Table 1 Demographics and clinical characteristics at study enrolment, stratified by patient group
Group 1 | Group 2 | Group 3 | |
|---|---|---|---|
(n = 89) | (n = 108) | (n = 102) | |
Patient characteristics | |||
Mean (SD) age (years) | 55.0 (11.1) | 57.7 (10.6) | 55.3 (11.2) |
Ethnicitya (n, %) | |||
White British | 75 (84.3%) | 101 (93.5%) | 83 (81.4%) |
Other | 10 (11.2%) | 7 (6.5%) | 15 (14.7%) |
Educationb | |||
GCSE (or equivalent) or higher (n, %) | 66 (74.2%) | 81 (75.0%) | 81 (79.4%) |
No formal qualifications | 21 (23.6%) | 26 (24.1%) | 19 (19.6%) |
≥ 1 clinically significant comorbiditiesc, (n, %) | 11 (12.4%) | 10 (9.3%) | 15 (14.7%) |
Disease characteristics | |||
Tumour stage (n, %) | |||
Stage I | 20 (22.5%) | 25 (23.1%) | 0 (0.0%) |
Stage II | 54 (60.7%) | 53 (49.1%) | 0 (0.0%) |
Stage III | 14 (15.7%) | 29 (26.9%) | 0 (0.0%) |
Stage IV | 0 (0.0%) | 0 (0.0%) | 101 (99.0%) |
Not recorded | 1 (1.1%) | 0 (0.0%) | 1 (1.0%) |
Hormone receptor-positive (n, %) | |||
Yes | 64 (71.9%) | 84 (77.8%) | 74 (72.5%) |
No | 25 (28.1%) | 24 (22.2%) | 26 (25.5%) |
Not known | 0 (0.0%) | 0 (0.0%) | 2 (2.0%) |
Median (IQR) time since early BC diagnosis (months) | 9.0 (6.0) | 45.0 (32.0) (n = 103) | 79.5 (82.0) (n = 71) |
Median (IQR) time since metastatic BC diagnosis (months) | 30.0 (37.0) | ||
Type of metastatic BC diagnosis (n, %) | |||
De novo | – | – | 27 (26.5%) |
Relapsed | – | – | 75 (73.5%) |
Sites of metastatic BC disease (n, %) | |||
Non-visceral | – | – | 23 (22.5%) |
Visceral involvement | – | – | 77 (75.5%) |
Visceral involvement unknown | – | – | 2 (2.0%) |
No CNS involvement | – | – | 71 (69.6%) |
CNS involvement | – | – | 25 (24.5%) |
CNS involvement unknown | – | – | 6 (5.9%) |